1208127-10-9

Basic information

• Product Name: 5-cyclopropyl-3-phenyl-1H-pyrazole
• Synonyms: 5-cyclopropyl-3-phenyl-1H-pyrazole
• CAS NO: 1208127-10-9
• Molecular Weight: 184.241
• Mol File: 1208127-10-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-cyclopropyl-3-phenyl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-cyclopropyl-3-phenyl-1H-pyrazole(1208127-10-9)
• EPA Substance Registry System: 5-cyclopropyl-3-phenyl-1H-pyrazole(1208127-10-9)

Safety Data

• Hazardous Substances Data: 1208127-10-9(Hazardous Substances Data)

Upstream product

• 30923-65-0 1-cyclopropyl-3-phenyl-1,3-propanedione 
• 6746-94-7 Cyclopropylacetylene 
• 100-52-7 benzaldehyde 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 98-86-2 acetophenone 

Downstream Products

• 1231308-06-7 5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazole 

Relevant articles and documents

PIKFYVE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.

Chemoselective synthesis of substituted pyrazoles through AgOTf-catalyzed cascade propargylic substitution-cyclization-aromatization

A cascade AgOTf-catalyzed chemoselective approach to 3,5/1,3-disubstitued pyrazoles from propargylic alcohols and para-tolylsulfonohydrazide has been developed. Good chemoselectivity is observed depending on the different substituents in the alkyne moiety of the propargylic alcohols, generating two different kinds of products through different aromatization mechanisms. The pyrazolo[5,1-a]isoquinoline skeleton can also be effectively constructed by this method through a cascade bicyclization process.

PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN(PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).